Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27495292,fm,"The fm,CYP2B6 was predicted to be 21%, and the fm,CYP2C19, 6% for racemic bupropion.","Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro. ",fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27495292/),%,21,2266,DB00208,Ticlopidine
,27495292,fm,"The fm,CYP2B6 was predicted to be 21%, and the fm,CYP2C19, 6% for racemic bupropion.","Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27495292/),%,6,2267,DB00208,Ticlopidine
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],1.6,3898,DB00208,Ticlopidine
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],2.9,3899,DB00208,Ticlopidine
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],3.1,3900,DB00208,Ticlopidine
,10440419,Cmax,"The mean Cmax values (+/-SD) for SR26334 following single doses of 50, 75, 100, and 150 mg were 1.6+/-0.30 mg/L, 2.9+/-0.68 mg/L, 3.1+/-0.94 mg/L, and 4.9+/-1.22 mg/L, respectively.",Pharmacokinetics of clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],4.9,3901,DB00208,Ticlopidine
,10440419,T(max),Median T(max)(0.8-1.0 hour) and mean plasma t1/2 (7.2-7.6 hours) values were not significantly different between doses.,Pharmacokinetics of clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),h,0.8-1.0,3902,DB00208,Ticlopidine
,10440419,plasma t1/2,Median T(max)(0.8-1.0 hour) and mean plasma t1/2 (7.2-7.6 hours) values were not significantly different between doses.,Pharmacokinetics of clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),h,7.2-7.6,3903,DB00208,Ticlopidine
,10440419,C(trough),"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.8,3904,DB00208,Ticlopidine
,10440419,C(trough),"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.11,3905,DB00208,Ticlopidine
,10440419,at steady state,"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.8,3906,DB00208,Ticlopidine
,10440419,at steady state,"Following repeated dosing with clopidogrel 75 mg, mean (+/-SD) C(trough) values (values before dosing) for SR26334 at steady state ranged from 0.8+/-0.04 mg/L to 0.11+/-0.07 mg/L.",Pharmacokinetics of clopidogrel. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440419/),[mg] / [l],0.11,3907,DB00208,Ticlopidine
>,23542721,recoveries,Assay recoveries were high (>79%).,A validated HPLC-MS/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23542721/),%,79,4074,DB00208,Ticlopidine
,31039046,IC50,Alcohol significantly inhibited the hydrolysis of clopidogrel (IC50 161 mM) and 2-oxo-clopidogrel (IC50 6 mM).,Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039046/),mM,161,8457,DB00208,Ticlopidine
,31039046,IC50,Alcohol significantly inhibited the hydrolysis of clopidogrel (IC50 161 mM) and 2-oxo-clopidogrel (IC50 6 mM).,Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31039046/),mM,6,8458,DB00208,Ticlopidine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],15.8,10569,DB00208,Ticlopidine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],0.113,10570,DB00208,Ticlopidine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],454,10571,DB00208,Ticlopidine
,19280520,areas under the plasma concentration versus time curve (AUC),"The areas under the plasma concentration versus time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg(-1)) and clopidogrel (0.77 mg kg(-1)) were 15.8 +/- 15.9 ng h ml(-1) and 0.113 +/- 0.226 ng h ml(-1), respectively, in rats, and 454 +/- 104 ng h ml(-1) and 23.3 +/- 4.3 ng h ml(-1), respectively, in dogs, indicating efficient hydrolysis of prasugrel and little metabolism of clopidogrel to their thiolactones in the intestine.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),[h·ng] / [ml],23.3,10572,DB00208,Ticlopidine
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,25,10573,DB00208,Ticlopidine
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,7,10574,DB00208,Ticlopidine
,19280520,relative bioavailability,"The relative bioavailability of the active metabolites of prasugrel and clopidogrel calculated by the ratio of active metabolite AUC (prodrug oral administration/active metabolite intravenous administration) were 25% and 7%, respectively, in rats, and 25% and 10%, respectively, in dogs.",Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19280520/),%,10,10575,DB00208,Ticlopidine
,17141580,flow rate,Analysis was performed using a C8 column (temperature controlled to 50 degrees C) by gradient elution at a flow rate of 0.9 mL min(-1) over a 3 min run time.,The validation of a bioanalytical method for the determination of clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141580/),[ml] / [min],0.9,11937,DB00208,Ticlopidine
,17141580,Retention times,"Retention times of 1.61 and 1.59 min were observed for clopidogrel and 2H3-clopidogrel (I.S.), respectively.",The validation of a bioanalytical method for the determination of clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141580/),min,1.61,11938,DB00208,Ticlopidine
,17141580,Retention times,"Retention times of 1.61 and 1.59 min were observed for clopidogrel and 2H3-clopidogrel (I.S.), respectively.",The validation of a bioanalytical method for the determination of clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17141580/),min,1.59,11939,DB00208,Ticlopidine
,21666702,IC₅₀,"Ticlopidine inhibited CYP2C9 and 3A4 with IC₅₀ values of 26.0 and 32.3 μmol/L, respectively.",Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21666702/),[μM] / [l],26.0,13337,DB00208,Ticlopidine
,21666702,IC₅₀,"Ticlopidine inhibited CYP2C9 and 3A4 with IC₅₀ values of 26.0 and 32.3 μmol/L, respectively.",Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21666702/),[μM] / [l],32.3,13338,DB00208,Ticlopidine
,19634511,AUC(0-tlast),"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[h·pg] / [ml],"3,656.01",13350,DB00208,Ticlopidine
,19634511,AUC(0-tlast),"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[h·pg] / [ml],3771.51,13351,DB00208,Ticlopidine
,19634511,Cmax,"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[pg] / [ml],1970.22,13352,DB00208,Ticlopidine
,19634511,Cmax,"The arithmetic means of AUC(0-tlast) and Cmax were 3,656.01 pg x h/ml and 1970.22 pg/ml for the test formulation and 3771.51 pg x h/ml and 1756.52 pg/ml, respectively, for the reference formulation.",Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),[pg] / [ml],1756.52,13353,DB00208,Ticlopidine
,19634511,tmax,The mean tmax was 1.16 h for the test and 1.13 h for the reference formulation.,Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),h,1.16,13354,DB00208,Ticlopidine
,19634511,tmax,The mean tmax was 1.16 h for the test and 1.13 h for the reference formulation.,Bioequivalence study of two different clopidogrel bisulfate film-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634511/),h,1.13,13355,DB00208,Ticlopidine
,26695516,dose-adjusted concentrations,"Due to differences in the maintenance doses, we have calculated the dose-adjusted concentrations of clopidogrel (0.2 ng/ml/mg (0.1-0.4)) and 2-oxo-clopidogrel (2.1 ng/ml/mg (0.5-4.6)).",P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26695516/),[ng] / [mg·ml],0.2,14616,DB00208,Ticlopidine
,26695516,dose-adjusted concentrations,"Due to differences in the maintenance doses, we have calculated the dose-adjusted concentrations of clopidogrel (0.2 ng/ml/mg (0.1-0.4)) and 2-oxo-clopidogrel (2.1 ng/ml/mg (0.5-4.6)).",P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26695516/),[ng] / [mg·ml],2.1,14617,DB00208,Ticlopidine
better,9892073,extraction efficiency,The extraction efficiency was better than 48% over the range studied; for the internal standard it averaged 51% at 50 ng/ml.,Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892073/),%,48,16348,DB00208,Ticlopidine
,9892073,extraction efficiency,The extraction efficiency was better than 48% over the range studied; for the internal standard it averaged 51% at 50 ng/ml.,Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892073/),%,51,16349,DB00208,Ticlopidine
,24710841,AUC,"Similarly, PMs needed 300 mg daily to achieve active metabolite concentrations that were similar to EMs on 75 mg (AUC 37.7 and 33.5 ng h/mL, respectively).",Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710841/),[h·ng] / [ml],37.7,18438,DB00208,Ticlopidine
,24710841,AUC,"Similarly, PMs needed 300 mg daily to achieve active metabolite concentrations that were similar to EMs on 75 mg (AUC 37.7 and 33.5 ng h/mL, respectively).",Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24710841/),[h·ng] / [ml],33.5,18439,DB00208,Ticlopidine
,10440421,AUC ratio,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.021,21263,DB00208,Ticlopidine
,10440421,AUC ratio,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.001,21264,DB00208,Ticlopidine
,10440421,t 1/2 ratios,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.019,21265,DB00208,Ticlopidine
,10440421,t 1/2 ratios,"No significant change in the disposition of antipyrine was observed after the ingestion of clopidogrel over 10 days: mean AUC ratio (+/-SEM) for plasma antipyrine was 1.021+/-0.023 for the clopidogrel group versus 1.001+/-0.019 for the placebo group; mean day 10/day -2 t 1/2 ratios were 1.019+/-0.018 and 1.027+/-0.023, respectively.",Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440421/),,1.027,21266,DB00208,Ticlopidine
,31468659,area under the plasma-concentration-time curve (AUC0-24 ),Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel.,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468659/),[h·ng] / [ml],174.7,24233,DB00208,Ticlopidine
,31468659,area under the plasma-concentration-time curve (AUC0-24 ),Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel.,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468659/),[h·ng] / [ml],142.2,24234,DB00208,Ticlopidine
,20642549,t(max),"Ticagrelor was absorbed with median t(max) 1.5-3 h, exhibiting predictable pharmacokinetics over the 50-600 mg dose range.","Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642549/),h,1.5-3,25985,DB00208,Ticlopidine
>,29451685,recoveries,"The recoveries of edoxaban and the internal standard (ticlopidine) from human plasma were >85%, and the within- and between-day coefficients of variation were within 15%.","A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451685/),%,85,26664,DB00208,Ticlopidine
,29451685,absorption time lag,"Analysis of edoxaban pharmacokinetics demonstrated an absorption time lag of 4h, a maximum concentration of 110 ± 26 ng/mL and an oral clearance of 37 ± 16 L/h.","A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451685/),h,4,26665,DB00208,Ticlopidine
,29451685,maximum concentration,"Analysis of edoxaban pharmacokinetics demonstrated an absorption time lag of 4h, a maximum concentration of 110 ± 26 ng/mL and an oral clearance of 37 ± 16 L/h.","A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451685/),[ng] / [ml],110,26666,DB00208,Ticlopidine
,29451685,oral clearance,"Analysis of edoxaban pharmacokinetics demonstrated an absorption time lag of 4h, a maximum concentration of 110 ± 26 ng/mL and an oral clearance of 37 ± 16 L/h.","A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451685/),[l] / [h],37,26667,DB00208,Ticlopidine
,21827046,AUC(0-infinity),"The AUC(0-infinity) of CP was 13.78 +/- 0.67 and 11.46 +/- 1.98 ng/ mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [h·ml],13.78,27508,DB00208,Ticlopidine
,21827046,AUC(0-infinity),"The AUC(0-infinity) of CP was 13.78 +/- 0.67 and 11.46 +/- 1.98 ng/ mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [h·ml],11.46,27509,DB00208,Ticlopidine
,21827046,AUC(0-infinity),"The AUC(0-infinity) of IM was 33.08 +/- 5.76 and 21.67 +/- 8.95 microg/mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [h·ml],33.08,27510,DB00208,Ticlopidine
,21827046,AUC(0-infinity),"The AUC(0-infinity) of IM was 33.08 +/- 5.76 and 21.67 +/- 8.95 microg/mL x h for CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [h·ml],21.67,27511,DB00208,Ticlopidine
,21827046,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [ml],3.81,27512,DB00208,Ticlopidine
,21827046,maximum plasma concentration (C(max)),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[ng] / [ml],3.18,27513,DB00208,Ticlopidine
,21827046,C(max),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [ml],3.42,27514,DB00208,Ticlopidine
,21827046,C(max),"The maximum plasma concentration (C(max)) of CP was 3.81 +/- 0.54 ng/mL for CP form I and 3.18 +/- 0.31 ng/mL for CP form II, the C(max) of IM was 3.42 +/- 0.41 and 2.08 +/- 0.68 microg/ mL for the CP form I and form II, respectively.",Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827046/),[μg] / [ml],2.08,27515,DB00208,Ticlopidine
,20533345,LOQ,The lower LOQ was 0.8 ng/mL.,Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20533345/),[ng] / [ml],0.8,30466,DB00208,Ticlopidine
,18829199,recovery efficiencies,The derivatized samples were subjected to solid-phase extraction with a C2 disk plate and the overall procedure exhibited good reaction (more than 90%) and recovery efficiencies (from 85% to 105%).,Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829199/),%,85,30970,DB00208,Ticlopidine
,18829199,recovery efficiencies,The derivatized samples were subjected to solid-phase extraction with a C2 disk plate and the overall procedure exhibited good reaction (more than 90%) and recovery efficiencies (from 85% to 105%).,Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18829199/),%,105,30971,DB00208,Ticlopidine
,25609600,flow rate,The system was operated at 25°C using a mobile phase consisting of acetonitrile and phosphate buffer (pH 3.0) in the gradient ratio at a flow rate of 1 mL min(-1) with ultraviolet detection monitored at 232 nm.,"Liquid Chromatographic Method for Simultaneous Quantitation of Clopidogrel, Aspirin and Atorvastatin in Rat Plasma and Its Application to the Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25609600/),[ml] / [min],1,32433,DB00208,Ticlopidine
<,31189083,bioavailability,"Clopidogrel bisulfate (CB) is a golden antiplatelet treatment, yet its benefits are limited by its low bioavailability (<50%) caused by poor intestinal solubility and absorption.",Stabilizing excipients for engineered clopidogrel bisulfate procubosome derived in situ cubosomes for enhanced intestinal dissolution: Stability and bioavailability considerations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31189083/),%,50,32964,DB00208,Ticlopidine
,31189083,relative bioavailability,"Moreover, following oral administration in rabbits, CF2 showed higher relative bioavailability (153%) compared to commercial Plavix® with significant higher Cmax,shorter tmax, as well as enhanced antiplatelet activity.",Stabilizing excipients for engineered clopidogrel bisulfate procubosome derived in situ cubosomes for enhanced intestinal dissolution: Stability and bioavailability considerations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31189083/),%,153,32965,DB00208,Ticlopidine
,21656175,C(max),"The concentrations ranged up to 1,048.684 ng/mL, with a mean of 470.268 ng/mL, while clopidogrel had a mean C(max) of 1.348 ng/mL; these orders of magnitude show how much the back-conversion of this metabolite may influence clopidogrel quantification if it is not properly controlled.","Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21656175/),[ng] / [ml],1.348,33006,DB00208,Ticlopidine
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 µl⋅min-1⋅mg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],2.42,34460,DB00208,Ticlopidine
,29138287,"CLint,u","UGT2B7 and UGT2B17 exhibited the greatest level of clopidogrel carboxylic acid glucuronidation activities, with a CLint,u of 2.42 and 2.82 µl⋅min-1⋅mg-1, respectively.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],2.82,34461,DB00208,Ticlopidine
,29138287,CLint,"Of other enzymes displaying activity (UGT1A3, UGT1A9, UGT1A10-H, and UGT2B4), UGT2B4 (CLint,u 0.51 µl⋅min-1⋅mg-1) was estimated to contribute significantly to the hepatic clearance.","Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions . ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138287/),[μl] / [mg·min],0.51,34462,DB00208,Ticlopidine
,16977589,flow rate,The flow rate was set at 0.9 mL/min.,Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16977589/),[ml] / [min],0.9,34954,DB00208,Ticlopidine
,16977589,total run time of analysis,Ticlopidine was used as internal standard and the total run time of analysis was about 12 min.,Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16977589/),min,12,34955,DB00208,Ticlopidine
,16406450,flow rate,The flow rate was set at 0.2 mL/min.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),[ml] / [min],0.2,35009,DB00208,Ticlopidine
,16406450,time of analysis,Repaglinide was chosen as an internal standard and the time of analysis was 12 min.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),min,12,35010,DB00208,Ticlopidine
,16406450,extraction recovery,The extraction recovery of SR26334 from plasma was within the range of 85-90%.,Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16406450/),%,85-90,35011,DB00208,Ticlopidine
,16272957,accumulation ratio,"No significant intergenotypic differences in the pharmacokinetic parameters of ticlopidine were observed, although the accumulation ratio tended to be greater in hmEMs than in PMs (2.4 +/- 0.2 versus 1.7 +/- 0.2).","Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272957/),,2.4,40201,DB00208,Ticlopidine
,16272957,accumulation ratio,"No significant intergenotypic differences in the pharmacokinetic parameters of ticlopidine were observed, although the accumulation ratio tended to be greater in hmEMs than in PMs (2.4 +/- 0.2 versus 1.7 +/- 0.2).","Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272957/),,1.7,40202,DB00208,Ticlopidine
,21617016,k(tr),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],5.97,40381,DB00208,Ticlopidine
,21617016,k(e) (elimination rate constant),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],0.126,40382,DB00208,Ticlopidine
,21617016,k(d) (distribution rate constant),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],0.212,40383,DB00208,Ticlopidine
,21617016,V(2) (volume of central compartment),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),l,21.0,40384,DB00208,Ticlopidine
,21617016,V(3) (volume of peripheral compartment),"The typical point estimates of PK were k(tr) (identical transfer rate constant) = 5.97 h(-1), k(e) (elimination rate constant) = 0.126 h(-1), k(d) (distribution rate constant) = 0.212 h(-1), V(2) (volume of central compartment) = 21.0 L, and V(3) (volume of peripheral compartment) = 38.8 L.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),l,38.8,40385,DB00208,Ticlopidine
,21617016,k(in) (input rate),"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],27.9,40386,DB00208,Ticlopidine
,21617016,E(max) (maximum effect on input rate),"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),1/[h],0.292,40387,DB00208,Ticlopidine
,21617016,EC(5) (0),"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),[ng] / [ml],0.00629,40388,DB00208,Ticlopidine
,21617016,effective concentration,"The typical point estimates of PD were k(in) (input rate) = 27.9 h(-1), E(max) (maximum effect on input rate) = 0.292 h(-1), EC(5) (0) (median effective concentration) = 0.00629 ng/mL, and BASE (predose aggregation) = 66.7%.",Population pharmacokinetic/pharmacodynamic modeling of clopidogrel in Korean healthy volunteers and stroke patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21617016/),[ng] / [ml],0.00629,40389,DB00208,Ticlopidine
,20171421,C(max),"The geometric mean C(max) for the test and reference formulations was 877.76 and 913.49 pg/mL, respectively.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[pg] / [ml],877.76,50402,DB00208,Ticlopidine
,20171421,C(max),"The geometric mean C(max) for the test and reference formulations was 877.76 and 913.49 pg/mL, respectively.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[pg] / [ml],913.49,50403,DB00208,Ticlopidine
,20171421,AUC(0-t),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],1911.53,50404,DB00208,Ticlopidine
,20171421,AUC(0-t),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2053.09,50405,DB00208,Ticlopidine
,20171421,AUC(0-infinity)),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2021.33,50406,DB00208,Ticlopidine
,20171421,AUC(0-infinity)),"The geometric mean AUC(0-t) was 1911.53 and 2053.09 pg . h/mL, and the geometric mean AUC(0-infinity)) was 2021.33 and 2188.25 pg . h/mL.","Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171421/),[h·pg] / [ml],2188.25,50407,DB00208,Ticlopidine
,1815063,rate,"With HPLC, a mobile phase of 0.01 M pH 7.8 phosphate buffer:acetonitrile (70:30) was passed through a mu Bondapack C-18 column at a rate of 1.3 mL/min.","Quantitative high-performance liquid chromatographic, gas chromatographic, and gas chromatographic-mass spectrometric analysis of ticlopidine in baboon plasma after solid-phase extraction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815063/),[ml] / [min],1.3,52788,DB00208,Ticlopidine
more,15935741,extraction efficiency,The extraction efficiency for the carboxylic acid metabolite of clopidogrel was more than 85.76%.,Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15935741/),%,85.76,56303,DB00208,Ticlopidine
,10440423,Cmax,"For the fed/fasting study, mean Cmax values (+/-SD) were 2.7+/-0.62 mg/L and 2.1+/-0.96 mg/L for the fasting state and the fed state, respectively and the 90% CI of Cmax ratio was [0.57 - 0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.7,58522,DB00208,Ticlopidine
,10440423,Cmax,"For the fed/fasting study, mean Cmax values (+/-SD) were 2.7+/-0.62 mg/L and 2.1+/-0.96 mg/L for the fasting state and the fed state, respectively and the 90% CI of Cmax ratio was [0.57 - 0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.1,58523,DB00208,Ticlopidine
,10440423,AUC(0-obs),"Mean AUC(0-obs) values (AUC to the last observed value) were 7.1+/-1.6 mg.h/L and 7.4+/-1.64 mg.h/L, respectively, and the 90% Cl of AUC ratios were [0.90 - 1.02] and [0.89 - 0.97], respectively.",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],7.1,58524,DB00208,Ticlopidine
,10440423,AUC(0-obs),"Mean AUC(0-obs) values (AUC to the last observed value) were 7.1+/-1.6 mg.h/L and 7.4+/-1.64 mg.h/L, respectively, and the 90% Cl of AUC ratios were [0.90 - 1.02] and [0.89 - 0.97], respectively.",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],7.4,58525,DB00208,Ticlopidine
,10440423,Cmax,"For the antacid study, mean Cmax values were 2.6+/-0.84 mg/L and 2.5+/-0.87 mg/L for the no-antacid regimen and the antacid regimen, respectively, and the 90% CI of Cmax ratio was [0.74 - 1.16].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.6,58526,DB00208,Ticlopidine
,10440423,Cmax,"For the antacid study, mean Cmax values were 2.6+/-0.84 mg/L and 2.5+/-0.87 mg/L for the no-antacid regimen and the antacid regimen, respectively, and the 90% CI of Cmax ratio was [0.74 - 1.16].",Clopidogrel bioavailability: absence of influence of food or antacids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[mg] / [l],2.5,58527,DB00208,Ticlopidine
,10440423,AUC(0-obs),"Mean AUC(0-obs) values were 6.3+/-1.34 mg.h/L and 5.8+/-1.33 mg.h/L, respectively, and the 90% CI of AUC ratios was [0.89+/-0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],6.3,58528,DB00208,Ticlopidine
,10440423,AUC(0-obs),"Mean AUC(0-obs) values were 6.3+/-1.34 mg.h/L and 5.8+/-1.33 mg.h/L, respectively, and the 90% CI of AUC ratios was [0.89+/-0.97].",Clopidogrel bioavailability: absence of influence of food or antacids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440423/),[h·mg] / [l],5.8,58529,DB00208,Ticlopidine
,19496900,peak,"Plasma SR26334 concentrations peaked earlier after crushed delivery than after oral intake (44 vs. 70 minutes, P = 0.023) and the median peak was 80% higher (13,083 vs. 7,255 ng/mL, respectively, P = 0.021).",Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19496900/),[ng] / [ml],"13,083",65198,DB00208,Ticlopidine
,19496900,peak,"Plasma SR26334 concentrations peaked earlier after crushed delivery than after oral intake (44 vs. 70 minutes, P = 0.023) and the median peak was 80% higher (13,083 vs. 7,255 ng/mL, respectively, P = 0.021).",Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19496900/),[ng] / [ml],"7,255",65199,DB00208,Ticlopidine
,26576037,maximal concentration (Cmax ),"CAM reached maximal concentration (Cmax ) (median, 110.8 nm; range, 41.9-484.8) 0.5-2 h after the loading dose.",Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26576037/),nm,110.8,66213,DB00208,Ticlopidine
,26576037,IC50,"A sigmoid dose-response curve defined the relations between CAMCmax and PRI after 3 to 24 h (IC50 , 459.6 nm; 95% confidence interval, 453.4-465.7; R(2) = 0.82).",Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26576037/),nm,459.6,66214,DB00208,Ticlopidine
,27459888,Cmax,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],0.4,68425,DB00208,Ticlopidine
,27459888,Cmax,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],1.7,68426,DB00208,Ticlopidine
,27459888,AUC0-∞,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [mlh],0.9,68427,DB00208,Ticlopidine
,27459888,AUC0-∞,"After pretreatment with DZSM, the Cmax and AUC0-∞ of clopidogrel increased from 0.4±0.1 to 1.7±0.6ng/mL and 0.9±0.4 to 2.0±0.2ng/mLh, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [mlh],2.0,68428,DB00208,Ticlopidine
,27459888,Cmax,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],8.2,68429,DB00208,Ticlopidine
,27459888,Cmax,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ng] / [ml],2.8,68430,DB00208,Ticlopidine
,27459888,AUC0-∞,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ngh] / [ml],18.2,68431,DB00208,Ticlopidine
,27459888,AUC0-∞,"The Cmax and AUC0-∞ of the derivatized active metabolite of clopidogrel decreased from 8.2±1.2 to 2.8±0.5ng/mL and 18.2±5.6 to 6.4±3.7ngh/mL, respectively.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[ngh] / [ml],6.4,68432,DB00208,Ticlopidine
,27459888,IC50,"In rat liver microsomes, DZSM inhibited clopidogrel metabolism with an IC50 of 0.02mg/mL.",Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27459888/),[mg] / [ml],0.02,68433,DB00208,Ticlopidine
,1768571,"area under the curve, AUC (0-12 h)","After a single 250 mg dose of ticlopidine, the mean area under the curve, AUC (0-12 h) was 1.11 micrograms ml-1 h in young subjects and 2.04 micrograms ml-1 h in old subjects (P = 0.002).",Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768571/),[h·μg] / [ml],1.11,73663,DB00208,Ticlopidine
,1768571,"area under the curve, AUC (0-12 h)","After a single 250 mg dose of ticlopidine, the mean area under the curve, AUC (0-12 h) was 1.11 micrograms ml-1 h in young subjects and 2.04 micrograms ml-1 h in old subjects (P = 0.002).",Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768571/),[h·μg] / [ml],2.04,73664,DB00208,Ticlopidine
,1768571,"t1/2,z","Mean values of t1/2,z in young and elderly subjects were 7.9 h and 12.6 h, respectively (P = 0.01).",Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768571/),h,7.9,73665,DB00208,Ticlopidine
,1768571,"t1/2,z","Mean values of t1/2,z in young and elderly subjects were 7.9 h and 12.6 h, respectively (P = 0.01).",Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768571/),h,12.6,73666,DB00208,Ticlopidine
,1768571,"plasma t1/2,z","The plasma t1/2,z averaged 4.0 days for young subjects and 3.8 days for elderly subjects (P = 0.7).",Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768571/),d,4.0,73667,DB00208,Ticlopidine
,1768571,"plasma t1/2,z","The plasma t1/2,z averaged 4.0 days for young subjects and 3.8 days for elderly subjects (P = 0.7).",Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768571/),d,3.8,73668,DB00208,Ticlopidine
,10761167,in,"At Day 10, there was not a statistically significant difference in mean inhibition of platelet aggregation (49.2% +/- 38.6% in cirrhotics vs. 66.7% +/- 7.5% in normals) or in bleeding time prolongation factor (1.64 +/- 0.49 in cirrhotics vs. 1.54 +/- 0.87 in normals) between groups.",Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761167/),%,49.2,75146,DB00208,Ticlopidine
,10761167,in,"At Day 10, there was not a statistically significant difference in mean inhibition of platelet aggregation (49.2% +/- 38.6% in cirrhotics vs. 66.7% +/- 7.5% in normals) or in bleeding time prolongation factor (1.64 +/- 0.49 in cirrhotics vs. 1.54 +/- 0.87 in normals) between groups.",Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761167/),%,66.,75147,DB00208,Ticlopidine
,23016454,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax) was higher in the 681GA+681AA group than that in the 681GG group (1.93 +/- 1.77 vs. 1.65 +/- 1.56ng/mL, P=0.613).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[ng] / [ml],1.93,79108,DB00208,Ticlopidine
,23016454,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax) was higher in the 681GA+681AA group than that in the 681GG group (1.93 +/- 1.77 vs. 1.65 +/- 1.56ng/mL, P=0.613).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[ng] / [ml],1.65,79109,DB00208,Ticlopidine
,23016454,area under the curve to the last measurable concentration (AUC(0-36)),The area under the curve to the last measurable concentration (AUC(0-36)) and area under the curve extrapolated to infinity (AUC(0-infinity)) of clopidogrel were lower in the 681GG group than that in the 681GA+ 681AA group (2.25 +/- 1.64 vs.,CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),,2.25,79110,DB00208,Ticlopidine
,23016454,oral clearance (CI/F),"The oral clearance (CI/F) was lower in the 681GA+681AA group than that in the 681GG group (51.96 +/- 36.13 vs. 54.47 +/- 35.21 x 10(3) L/h, P=0.829).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[l] / [h],51.96,79111,DB00208,Ticlopidine
,23016454,oral clearance (CI/F),"The oral clearance (CI/F) was lower in the 681GA+681AA group than that in the 681GG group (51.96 +/- 36.13 vs. 54.47 +/- 35.21 x 10(3) L/h, P=0.829).",CYP2C19 681G > A polymorphism and pharmacokinetics of clopidogrel in Chinese healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016454/),[l] / [h],54.47,79112,DB00208,Ticlopidine
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),min,30,79419,DB00208,Ticlopidine
,17174640,time to reach >,"For 20 micromol/L ADP, the median time to reach > or = 20% IPA was 30 minutes for prasugrel and 1.5 hours for clopidogrel (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),h,1.5,79420,DB00208,Ticlopidine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,84.1,79421,DB00208,Ticlopidine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,48.9,79422,DB00208,Ticlopidine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,78.8,79423,DB00208,Ticlopidine
,17174640,maximum IPA,"The maximum IPA was 84.1% +/- 9.5% with prasugrel versus 48.9% +/- 27.0% with clopidogrel for 5 micromol/L ADP and 78.8% +/- 9.2% versus 35.0% +/- 24.5%, respectively, for 20 micromol/L ADP (P < .001).",A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17174640/),%,35.0,79424,DB00208,Ticlopidine
,7795822,flow-rate,"Chromatography was performed isocratically with acetonitrile-methanol-0.05 M KH2PO4 (20:25:55, v/v) at pH 3.0 containing 3% triethylamine at a flow-rate of 1 ml/min.",Determination of ticlopidine in human plasma by high-performance liquid chromatography and ultraviolet absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795822/),[ml] / [min],1,88995,DB00208,Ticlopidine
,15497667,AUC0-inf,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],29.94,90435,DB00208,Ticlopidine
,15497667,AUC0-t,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],29.53,90436,DB00208,Ticlopidine
,15497667,AUC0-t,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],29.24,90437,DB00208,Ticlopidine
,15497667,AUC0-t,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[h·ng] / [ml],28.83,90438,DB00208,Ticlopidine
,15497667,Cmax,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[ng] / [ml],7.386,90439,DB00208,Ticlopidine
,15497667,Cmax,"The mean AUC0-inf, AUC0-t and Cmax were 29.94 ng x h/mL, 29.53 ng x h/mL and 7.386 ng/mL, respectively, for the test formulation and 29.24 ng x h/mL, 28.83 ng x h/mL and 7.921 ng/mL, respectively, for the reference formulation.",Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),[ng] / [ml],7.921,90440,DB00208,Ticlopidine
,15497667,Tmax,The median Tmax for both formulations was 1.25 h.,Bioequivalence study of clopidogrel bisulfate film-coated tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497667/),h,1.25,90441,DB00208,Ticlopidine
,31868554,Vmax,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 ± 11.20 pmol/min/mg, 11.10 ± 1.07 μM, and 23.10 ± 1.32 μL/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),[pM] / [mg·min],256.41,92177,DB00208,Ticlopidine
,31868554,Km,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 ± 11.20 pmol/min/mg, 11.10 ± 1.07 μM, and 23.10 ± 1.32 μL/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),μM,11.10,92178,DB00208,Ticlopidine
,31868554,CLint,"Results: The Vmax, Km, and CLint of 23-HBA were 256.41 ± 11.20 pmol/min/mg, 11.10 ± 1.07 μM, and 23.10 ± 1.32 μL/min/mg, respectively.",Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31868554/),[μl] / [mg·min],23.10,92179,DB00208,Ticlopidine
,10718778,bleeding time,The bleeding time was prolonged in the treatments with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) compared with sibrafiban alone (3.5 min).,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718778/),min,8.1,93777,DB00208,Ticlopidine
,10718778,bleeding time,The bleeding time was prolonged in the treatments with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) compared with sibrafiban alone (3.5 min).,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718778/),min,8. 6,93778,DB00208,Ticlopidine
,10718778,bleeding time,The bleeding time was prolonged in the treatments with ticlopidine/aspirin (8.1 min) and sibrafiban/ticlopidine/aspirin (8. 6 min) compared with sibrafiban alone (3.5 min).,Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10718778/),min,3.5,93779,DB00208,Ticlopidine
,10385210,t1/1beta,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),h,1.04,108518,DB00208,Ticlopidine
,10385210,t1/1beta,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),h,4,108519,DB00208,Ticlopidine
,10385210,t1/1beta,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),h,12.80,108520,DB00208,Ticlopidine
,10385210,Vdbeta/F,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),1/[lkg],214 31,108521,DB00208,Ticlopidine
,10385210,Vdbeta/F,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),1/[lkg],475,108522,DB00208,Ticlopidine
,10385210,Vdbeta/F,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),1/[lkg],221,108523,DB00208,Ticlopidine
,10385210,Vdbeta/F,"For example, t1/1beta for the 10, 50 and 100 mgkg(-1) doses were 1.04+/-0.10, 4+/-24+/-1.92 and 12.80+/-6.35 h, respectively, whereas the Vdbeta/F values for the corresponding doses were 214 31, 475 221 and 998+/-420 Lkg(-1), respectively.",Pharmacokinetics of ticlopidine in the rabbit. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385210/),1/[lkg],998,108524,DB00208,Ticlopidine
,33244163,Tmax,"Vicagrel absorption was fast (Tmax = 0.625 h), and the mean t1/2 of vicagrel-related components was ~38.0 h in both plasma and blood.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),h,0.625,110389,DB00208,Ticlopidine
,33244163,t1/2,"Vicagrel absorption was fast (Tmax = 0.625 h), and the mean t1/2 of vicagrel-related components was ~38.0 h in both plasma and blood.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),h,38.0,110390,DB00208,Ticlopidine
,33244163,blood-to-plasma radioactivity AUCinf ratio,"The blood-to-plasma radioactivity AUCinf ratio was 0.55, suggesting preferential distribution of drug-related material in plasma.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),,0.55,110391,DB00208,Ticlopidine
,33244163,cumulative excreted radioactivity,"At 168 h after oral administration, the mean cumulative excreted radioactivity was 96.71% of the dose, including 68.03% in urine and 28.67% in feces.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),,68,110392,DB00208,Ticlopidine
,33244163,cumulative excreted radioactivity,"At 168 h after oral administration, the mean cumulative excreted radioactivity was 96.71% of the dose, including 68.03% in urine and 28.67% in feces.","Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33244163/),%,28,110393,DB00208,Ticlopidine
,11095576,half-lives,"Nonenzymatic chiral inversion of clopidogrel at 37 degrees C in 0.1 M phosphate buffers could be observed but was found to be slow, with estimated half-lives of 7 to 12 days, depending on the pH.",Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11095576/),d,7 to 12,113210,DB00208,Ticlopidine
,8055680,terminal elimination half-life,The terminal elimination half-life is between 20 and 50 hours.,Clinical pharmacokinetics of ticlopidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8055680/),h,20 and 50,118182,DB00208,Ticlopidine
,17112805,flux,Inhibition of P-gp activity by different modulators increased the absorptive clopidogrel flux across Caco-2 monolayers from 0.51+/-0.19 pmol/cm2 (mean+/-SD) at baseline by a maximum of 5- to 9-fold (P<.001) and the intracellular accumulation from 0.99+/-0.11 pmol/mg protein by a maximum of 2.5-fold (P<.001) in response to 1-micromol/L clopidogrel and decreased clopidogrel efflux to the level of passive diffusion.,Impact of P-glycoprotein on clopidogrel absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[pM] / [cm2],0.51,118395,DB00208,Ticlopidine
,17112805,intracellular accumulation,Inhibition of P-gp activity by different modulators increased the absorptive clopidogrel flux across Caco-2 monolayers from 0.51+/-0.19 pmol/cm2 (mean+/-SD) at baseline by a maximum of 5- to 9-fold (P<.001) and the intracellular accumulation from 0.99+/-0.11 pmol/mg protein by a maximum of 2.5-fold (P<.001) in response to 1-micromol/L clopidogrel and decreased clopidogrel efflux to the level of passive diffusion.,Impact of P-glycoprotein on clopidogrel absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[pM] / [mg],0.99,118396,DB00208,Ticlopidine
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],13.3,118397,DB00208,Ticlopidine
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],2.5,118398,DB00208,Ticlopidine
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],49.7,118399,DB00208,Ticlopidine
,17112805,Cmax,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [ml],6.6,118400,DB00208,Ticlopidine
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],1502,118401,DB00208,Ticlopidine
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],209,118402,DB00208,Ticlopidine
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],7057,118403,DB00208,Ticlopidine
,17112805,AUC,"After the 600-mg loading dose, Cmax values (mean+/-SD) of clopidogrel and its active metabolite in 3435T/T carriers were 13.3+/-5.2 ng/mL and 2.5+/-1.2 ng/mL, respectively, compared with 49.7+/-41.6 ng/mL (P=.001) and 6.6+/-3.6 ng/mL (P=.011), respectively, in 3435C/T and 3435C/C carriers; AUC values were 1502+/-463 ng/mLxmin for clopidogrel and 209+/-99 ng/mL x min for its active metabolite in 3435T/T carriers compared with 7057+/-5443 ng/mLxmin (P=.0006) and 744+/-541 ng/mLxmin (P=.011), respectively, in 3435C/T and 3435C/C carriers.",Impact of P-glycoprotein on clopidogrel absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17112805/),[ng] / [min·ml],744,118404,DB00208,Ticlopidine
,1413873,peak plasma concentrations,"2. After the first dose, peak plasma concentrations (median 0.31, range 0.08-0.80 mg/l) were generally found at 2 h.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[mg] / [l],0.31,119062,DB00208,Ticlopidine
,1413873,AUC,The median AUC value for this first dosage interval (AUC tau) was 0.97 (range 0.41-3.49) mg h l-1.,Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[h·mg] / [l],0.97,119063,DB00208,Ticlopidine
,1413873,AUC tau),The median AUC value for this first dosage interval (AUC tau) was 0.97 (range 0.41-3.49) mg h l-1.,Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[h·mg] / [l],0.97,119064,DB00208,Ticlopidine
,1413873,half-life,"From 30 h after the final dose, drug levels declined exponentially with a median half-life of 28.8 (range less than or equal to 20-50) h. 4.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),h,28.8,119065,DB00208,Ticlopidine
,1413873,peak concentration,"Following the final dose, the median peak concentration and AUC tau were 0.99 (range 0.22-2.12) mg/l and 4.06 (range 0.90-15.2) mg h l-1 respectively.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[mg] / [l],0.99,119066,DB00208,Ticlopidine
,1413873,AUC tau,"Following the final dose, the median peak concentration and AUC tau were 0.99 (range 0.22-2.12) mg/l and 4.06 (range 0.90-15.2) mg h l-1 respectively.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),[h·mg] / [l],4.06,119067,DB00208,Ticlopidine
,1413873,accumulation factor,"Based on AUC values, the mean accumulation factor +/- SD was 3.73 +/- 1.14.",Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1413873/),,3.73,119068,DB00208,Ticlopidine
,19922896,B,Bleeding time was determined before dosing (0 hour) and at 5 and 24 hours after dosing.,"Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,0,120342,DB00208,Ticlopidine
,19922896,T(max),Median (range) T(max) of ticlopidine was 1.5 (0.5-2.0) hours in both groups.,"Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,1.5,120343,DB00208,Ticlopidine
,19922896,t((1/2)),"The mean (SD) t((1/2)) of ticlopidine in the combined fixed-dose formulation and the concomitant administration groups was 19.5 (3.4) and 19.0 (3.3) hours after study drug administration, respectively.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,19.5,120344,DB00208,Ticlopidine
,19922896,t((1/2)),"The mean (SD) t((1/2)) of ticlopidine in the combined fixed-dose formulation and the concomitant administration groups was 19.5 (3.4) and 19.0 (3.3) hours after study drug administration, respectively.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),h,19.0,120345,DB00208,Ticlopidine
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,4.5,120346,DB00208,Ticlopidine
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,5.4,120347,DB00208,Ticlopidine
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,4.4,120348,DB00208,Ticlopidine
,19922896,bleeding time,"The mean (SD) bleeding time at predose (0), and 5 and 24 hours after dose administration was 4.5 (1.6) to 5.4 (1.7) minutes in the combined fixed-dose formulation group and 4.4 (1.6) to 5.1 (1.1) minutes in the concomitant administration group.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,5.1,120349,DB00208,Ticlopidine
>,19922896,bleeding times,"Five subjects (3 in the combined fixed-dose formulation group and 2 in the concomitant administration group) had bleeding times >8 minutes, but this was not considered to be clinically significant.","Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19922896/),min,8,120350,DB00208,Ticlopidine
,17220050,t1/2,The t1/2 increased from 2.5 h in the fasted state to 5.0 h in the fed state.,Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220050/),h,2.5,122414,DB00208,Ticlopidine
,17220050,t1/2,The t1/2 increased from 2.5 h in the fasted state to 5.0 h in the fed state.,Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220050/),h,5.0,122415,DB00208,Ticlopidine
,16019950,terminal elimination half-life,"Upon intravenous (IV) administration, the concentration of DRF 4367 declined in a bi-exponential fashion with a terminal elimination half-life of 4.0 h.","Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),h,4.0,122554,DB00208,Ticlopidine
,16019950,volume of distribution,"The volume of distribution and systemic clearance of DRF 4367 in mice were 0.80 l h(-1) kg(-1) and 0.14 l kg(-1), respectively, after IV administration.","Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),[l] / [h·kg],0.80,122555,DB00208,Ticlopidine
,16019950,systemic clearance,"The volume of distribution and systemic clearance of DRF 4367 in mice were 0.80 l h(-1) kg(-1) and 0.14 l kg(-1), respectively, after IV administration.","Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),[l] / [kg],0.14,122556,DB00208,Ticlopidine
,16019950,absolute oral bioavailability,The absolute oral bioavailability of DRF 4367 was 44%.,"Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16019950/),%,44,122557,DB00208,Ticlopidine
greater,20346740,recovery,SPE recovery of the analytes from plasma and urine was comparable and greater than 80%.,Capillary zone electrophoresis method for determination of (+)-S clopidogrel carboxylic acid metabolite in human plasma and urine designed for biopharmaceutic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20346740/),%,80,127016,DB00208,Ticlopidine
,28914344,area under the time-concentration curve,"As a result, predicted area under the time-concentration curve values was lower in carriers of this allele, with median 5.94 ng h/ml (interquartile range 3.92-12.51 [ng∙h/ml]) vs. 12.70 ng h/ml in non-carriers (interquartile range, 7.00-19.39 [ng∙h/ml]), respectively (p = 0.004).",Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28914344/),[h·ng] / [ml],5.94,129747,DB00208,Ticlopidine
,28914344,area under the time-concentration curve,"As a result, predicted area under the time-concentration curve values was lower in carriers of this allele, with median 5.94 ng h/ml (interquartile range 3.92-12.51 [ng∙h/ml]) vs. 12.70 ng h/ml in non-carriers (interquartile range, 7.00-19.39 [ng∙h/ml]), respectively (p = 0.004).",Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28914344/),[h·ng] / [ml],12.70,129748,DB00208,Ticlopidine
,26681020,peak plasma concentration (Cmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[ng] / [ml],1351.101,131846,DB00208,Ticlopidine
,26681020,peak plasma concentration (Cmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[ng] / [ml],1184.652,131847,DB00208,Ticlopidine
,26681020,area under the curve,"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[h·ng] / [ml],2642.017,131848,DB00208,Ticlopidine
,26681020,area under the curve,"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),[h·ng] / [ml],2780.666,131849,DB00208,Ticlopidine
,26681020,time to reach Cmax (Tmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),h,0.789,131850,DB00208,Ticlopidine
,26681020,time to reach Cmax (Tmax),"The pharmacokinetic parameters of the test and reference preparations were as follows: peak plasma concentration (Cmax), 1351.101 ± 654.955 ng/mL and 1184.652 ± 607.713 ng/mL; area under the curve, 2642.017 ± 1093.848 ng·h/mL and 2780.666 ± 1283.100 ng·h/mL; and time to reach Cmax (Tmax), 0.789 ± 0.318 h and 0.953 ± 0.633 h, respectively.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),h,0.953,131851,DB00208,Ticlopidine
,26681020,relative bioavailability,"The relative bioavailability of the formulation was 101.7 ± 35.3%, which indicated that the test preparation was bioequivalent to the reference drug.",Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681020/),%,101.7,131852,DB00208,Ticlopidine
,17922078,Km,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),μM,12.3,134955,DB00208,Ticlopidine
,17922078,Vmax,"SYUIQ-5 metabolism in rat liver microsomes followed Michaelis-Menten kinetics, with Km and Vmax values of 12.3 microM and 2.01 nmol/min/mg protein, respectively.","Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17922078/),[nM] / [mg·min],2.01,134956,DB00208,Ticlopidine
,2401752,tmax,After postprandial treatment the rate and extent of absorption of ticlopidine was earlier and greater relative to fasting treatment [tmax = 1.71 +/- 0.33 hr (fed) vs 1.92 +/- 0.56 hr (fasting) and AUC0-infinity = 2.164 +/- 0.813 micrograms X hr/mL (fed) vs 1.808 +/- 1.052 micrograms X hr/mL (fasting)].,Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401752/),h,1.71,142273,DB00208,Ticlopidine
,2401752,tmax,After postprandial treatment the rate and extent of absorption of ticlopidine was earlier and greater relative to fasting treatment [tmax = 1.71 +/- 0.33 hr (fed) vs 1.92 +/- 0.56 hr (fasting) and AUC0-infinity = 2.164 +/- 0.813 micrograms X hr/mL (fed) vs 1.808 +/- 1.052 micrograms X hr/mL (fasting)].,Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401752/),h,1.92,142274,DB00208,Ticlopidine
,2401752,AUC0-infinity,After postprandial treatment the rate and extent of absorption of ticlopidine was earlier and greater relative to fasting treatment [tmax = 1.71 +/- 0.33 hr (fed) vs 1.92 +/- 0.56 hr (fasting) and AUC0-infinity = 2.164 +/- 0.813 micrograms X hr/mL (fed) vs 1.808 +/- 1.052 micrograms X hr/mL (fasting)].,Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401752/),[h·μg] / [ml],2.164,142275,DB00208,Ticlopidine
,2401752,AUC0-infinity,After postprandial treatment the rate and extent of absorption of ticlopidine was earlier and greater relative to fasting treatment [tmax = 1.71 +/- 0.33 hr (fed) vs 1.92 +/- 0.56 hr (fasting) and AUC0-infinity = 2.164 +/- 0.813 micrograms X hr/mL (fed) vs 1.808 +/- 1.052 micrograms X hr/mL (fasting)].,Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2401752/),[h·μg] / [ml],1.808,142276,DB00208,Ticlopidine
,9163256,absolute recovery,"The compounds were isolated from plasma by Bond Elut C18 solid-phase extraction, the mean absolute recovery was 84.9%.",[Validity of a liquid chromatographic (HPLC) method for the determination of ticlopidine in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163256/),%,84.9,149354,DB00208,Ticlopidine
,9163256,limit of detection,"The limit of quantitation was 10 ng/ml, the limit of detection was 5 ng/ml.",[Validity of a liquid chromatographic (HPLC) method for the determination of ticlopidine in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163256/),[ng] / [ml],5,149355,DB00208,Ticlopidine
,9055136,minimum concentrations,"By day 36 the minimum concentrations in plasma were identical (0.35 +/- 0.22 mg/L and 0.36 +/- 0.21 mg/L, respectively).",Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055136/),[mg] / [l],0.35,153217,DB00208,Ticlopidine
,9055136,minimum concentrations,"By day 36 the minimum concentrations in plasma were identical (0.35 +/- 0.22 mg/L and 0.36 +/- 0.21 mg/L, respectively).",Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055136/),[mg] / [l],0.36,153218,DB00208,Ticlopidine
,18365698,hight,"When clopidogrel resinate was treated onto Caco-2 cell monolayers, clopidogrel, but not the resin, permeated across the cells with a hight permeation coefficient (Papp) of 13.5 +/- 1.13 x 10(-6) cm/sec.",The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365698/),[cm] / [s],13.5,156086,DB00208,Ticlopidine
,18365698,permeation coefficient (Papp),"When clopidogrel resinate was treated onto Caco-2 cell monolayers, clopidogrel, but not the resin, permeated across the cells with a hight permeation coefficient (Papp) of 13.5 +/- 1.13 x 10(-6) cm/sec.",The efficacy and safety of clopidogrel resinate as a novel polymeric salt form of clopidogrel. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365698/),[cm] / [s],13.5,156087,DB00208,Ticlopidine
,28921624,time to reach maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),h,8,162329,DB00208,Ticlopidine
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],355,162330,DB00208,Ticlopidine
,28921624,maximum concentration (Cmax ),"Ticagrelor and its active metabolite AR-C124910XX showed a similar time to reach maximum concentration (Cmax ) of 8 h, with the maximum concentration (Cmax ) of 355 (242.50-522.00) ng ml-1 and 63.20 (50.80-85.15) ng ml-1 , respectively.",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],63.20,162331,DB00208,Ticlopidine
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.67,162332,DB00208,Ticlopidine
,28921624,Cmax,"Both clopidogrel and its active metabolite approached the Cmax at 2 h, with a similar Cmax of 8.67 (6.64-27.75) ng ml-1 vs. 8.53 (6.94-15.93) ng ml-1 .",Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28921624/),[ng] / [ml],8.53,162333,DB00208,Ticlopidine
,10728490,K,"The estimated values +/- S.D. were 1.01 +/- 1.08 ml micrograms-1 hr-1 for K, 0.265 +/- 0.259 hr-1 for kr and 0.0747 +/- 0.0112 hr-1 for ke.",Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728490/),[ml] / [h·μg],1.01,164088,DB00208,Ticlopidine
,10728490,kr,"The estimated values +/- S.D. were 1.01 +/- 1.08 ml micrograms-1 hr-1 for K, 0.265 +/- 0.259 hr-1 for kr and 0.0747 +/- 0.0112 hr-1 for ke.",Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728490/),1/[h],0.265,164089,DB00208,Ticlopidine
,10728490,ke,"The estimated values +/- S.D. were 1.01 +/- 1.08 ml micrograms-1 hr-1 for K, 0.265 +/- 0.259 hr-1 for kr and 0.0747 +/- 0.0112 hr-1 for ke.",Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728490/),1/[h],0.0747,164090,DB00208,Ticlopidine
,10728490,life-span,"On the other hand, the mean life-span of platelets in the blood estimated by 1/ke after administration of ticlopidine was 14 hr, far below the life-span of platelets in the blood.",Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728490/),h,14,164091,DB00208,Ticlopidine
,10728490,1/ke,"On the other hand, the mean life-span of platelets in the blood estimated by 1/ke after administration of ticlopidine was 14 hr, far below the life-span of platelets in the blood.",Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10728490/),h,14,164092,DB00208,Ticlopidine
,21696537,area under the,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,54,166599,DB00208,Ticlopidine
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,66.3,166600,DB00208,Ticlopidine
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,47,166601,DB00208,Ticlopidine
,21696537,AUC,"Vasodilator stimulated phosphoprotein (VASP), platelet aggregometry (area under the curve (AUC)) and VerifyNow results were 54.7% ± 2.8 platelet reactivity index (PRI), 66.3 ± 2.6 AUC units and 213.1 ± 14.1 platelet reactivity units (PRU) with esomeprazole vs. 47% ± 2.7 PRI, 59.7 ± 3.7 AUC units and 181.4 ± 14.6 PRU with placebo (P < 0.01 esomeprazole vs. placebo for all measures).",Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),,59.7,166602,DB00208,Ticlopidine
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,68.9,166603,DB00208,Ticlopidine
,21696537,maximal aggregation,There was no significant difference in platelet aggregometry (maximal aggregation) between the esomeprazole group (68.9% ± 2.7 units) and placebo-treated group (64.5% ± 4.1 units; P > 0.05).,Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696537/),%,64.5,166604,DB00208,Ticlopidine
,21704146,time to peak plasma concentration (T(max)),FA was rapidly absorbed following oral administration with a mean time to peak plasma concentration (T(max)) of 0.03 h.,Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704146/),h,0.03,166719,DB00208,Ticlopidine
,21704146,maximum plasma concentration (C(max)),The corresponding maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC) were 8174.55 ng/L and 2594.45 h ng/mL respectively.,Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704146/),[ng] / [l],8174.55,166720,DB00208,Ticlopidine
,21704146,area under the concentration-time curve (AUC),The corresponding maximum plasma concentration (C(max)) and the area under the concentration-time curve (AUC) were 8174.55 ng/L and 2594.45 h ng/mL respectively.,Pharmacokinetics of ferulic acid and potential interactions with Honghua and clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704146/),[h·ng] / [ml],2594.45,166721,DB00208,Ticlopidine
,18613862,AUC(0-->infinity),"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [h·ml],6.24,170091,DB00208,Ticlopidine
,18613862,AUC(0-->infinity),"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [h·ml],8.93,170092,DB00208,Ticlopidine
,18613862,half-life,"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),,5.46,170093,DB00208,Ticlopidine
,18613862,half-life,"Smokers had lower AUC(0-->infinity) (smokers: 6.24 +/- 2.32 microg/h/mL vs. non-smokers: 8.93 +/- 3.80 microg/h/mL, P < 0.001) and shorter half-life (smokers: 5.46 +/- 2.99 vs. non-smokers: 8.43 +/- 4.26, P = 0.001).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),,8.43,170094,DB00208,Ticlopidine
,18613862,C(max),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [ml],3.09,170095,DB00208,Ticlopidine
,18613862,T(max),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),h,0.76,170096,DB00208,Ticlopidine
,18613862,AUC(0-->infinity),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),[μg] / [h·ml],7.98,170097,DB00208,Ticlopidine
,18613862,t(1/2e),"In general, the pharmacokinetic parameters were characterized by considerable inter-individual differences (C(max) = 3.09 +/- 0.99 microg/mL, CV = 32%), (T(max) =0.76 +/- 0.24 h, CV = 31.6%), (AUC(0-->infinity) = 7.98 +/- 3.58 microg/h/mL, CV = 44.8%), and (t(1/2e) = 7.38 +/- 4.10 h, CV = 55.6%).",Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18613862/),h,7.38,170098,DB00208,Ticlopidine
,527597,elimination half-life,"The elimination half-life, which was 1.56 +/- 0.08 days, was equivalent to the half-life measured after intravenous injection, and no difference in tissues distribution was observed.",The fate of ticlopidine in the organism. II.--Distribution and elimination of ticlopidine 14C after a single oral administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/527597/),d,1.56,175668,DB00208,Ticlopidine
,15578632,chromatographic run time,The method had a chromatographic run time of 3.0 min and a linear calibration curve over the range 1.0-1000 ng ml(-1) (r(2) > 0.999427).,Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578632/),min,3.0,175837,DB00208,Ticlopidine
,15578632,limit of quant,The limit of quantification was 1.0 ng ml(-1).,Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15578632/),[ng] / [ml],1.0,175838,DB00208,Ticlopidine
,33493742,flow rate,"The chromatographic separation was achieved on an Ultron ES-OVM column (150 × 2.0 mm, 5 μm) with acetonitrile-ammonium acetate (10 mM, pH 4.5) (22:78, v/v) at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493742/),[ml] / [min],0.3,176338,DB00208,Ticlopidine
>,33493742,extraction recovery,The extraction recovery was >90.2 % and no obvious matrix effect was observed.,Development and validation of a LC-MS/MS method for the enantioseparation and determination of clopidogrel bisulfate in beagle plasma and its application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33493742/),%,90.2,176339,DB00208,Ticlopidine
,19446152,C(max),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [ml],5.2,177642,DB00208,Ticlopidine
,19446152,T(max),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),h,0.9,177643,DB00208,Ticlopidine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [h·ml],10.1,177644,DB00208,Ticlopidine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [ml],5.4,177645,DB00208,Ticlopidine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),h,0.9,177646,DB00208,Ticlopidine
,19446152,AUC(0-t),"The mean values for C(max), T(max), and AUC(0-t) with clopidogrel (parent drug) of clopidogrel besylate (5.2 ng/mL, 0.9 hour, and 10.1 ng/mL/h, respectively) were similar to those with clopidogrel bisulfate (5.4 ng/mL, 0.9 hour, and 10.3 ng/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[ng] / [h·ml],10.3,177647,DB00208,Ticlopidine
,19446152,Cmax,"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [ml],10.9,177648,DB00208,Ticlopidine
,19446152,AUC(0-t),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],38.8,177649,DB00208,Ticlopidine
,19446152,AUC(0-t),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],40.6,177650,DB00208,Ticlopidine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],43.0,177651,DB00208,Ticlopidine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [ml],11.9,177652,DB00208,Ticlopidine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],40.6,177653,DB00208,Ticlopidine
,19446152,AUC(0-infinity),"The mean values for Cmax, AUC(0-t), and AUC(0-infinity) with the SR26334 of clopidogrel besylate (10.9 microg/mL, 38.8 microg/mL/h, and 43.0 microg/mL/h, respectively) were not significantly different from those with the SR26334 of clopidogrel bisulfate (11.9 microg/mL, 40.6 microg/mL/h, and 43.8 microg/mL/h).","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),[μg] / [h·ml],43.8,177654,DB00208,Ticlopidine
,19446152,maximal antiplatelet effect (Emax),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,58.8,177655,DB00208,Ticlopidine
,19446152,maximal antiplatelet effect (Emax),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,61.7,177656,DB00208,Ticlopidine
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,4299.1,177657,DB00208,Ticlopidine
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,61.7,177658,DB00208,Ticlopidine
,19446152,area under the time-effect curve (AUEC),"The mean values for maximal antiplatelet effect (Emax) and area under the time-effect curve (AUEC) with the 2 clopidogrel salt preparations were as follows: clopidogrel besylate, 58.8 h . % and 4299.1 h . % inhibition, respectively; and clopidogrel bisulfate, 61.7 h . % and 4406.9 h . % inhibition; these differences were not statistically significant.","Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446152/),%·h,4406.9,177659,DB00208,Ticlopidine
,22782539,bioavailability,"Similarly, clopidogrel bioavailability remained unchanged by chronic administration of dabigatran etexilate (part 3: ratio test/reference for AUC(0-24) was 103%; 90% CI 80.3-131%), as did its pharmacodynamic effects on the inhibition of platelet aggregation.",Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22782539/),%,103,180838,DB00208,Ticlopidine
,26071277,Emax,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),%,56,183118,DB00208,Ticlopidine
,26071277,EAUC50,"The relationship between inhibition of platelet aggregation (IPA, %) and the active metabolite AUC (h*μg/L) was described by a sigmoid function (Emax 56 ± 5%; EAUC50 15.9 ± 0.8 h*μg/L) with a gamma exponent (7.04 ± 2.26).","Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26071277/),[h·μg] / [l],15.9,183119,DB00208,Ticlopidine
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],45.39,190502,DB00208,Ticlopidine
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],29.15,190503,DB00208,Ticlopidine
,30017169,Cmax,"The mean CAM Cmax value was significantly higher in the NM group than in IM and PM groups (45.39 [12.57] vs 29.15 [7.92] ng/mL [P = 0.003] and 19.55 [2.19] ng/mL [P = 0.004], respectively).",Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[ng] / [ml],19.55,190504,DB00208,Ticlopidine
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],61.05,190505,DB00208,Ticlopidine
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],37.67,190506,DB00208,Ticlopidine
,30017169,AUC0-t,The mean CAM AUC0-t value was significantly higher in the NM group than in the IM and PM groups (61.05 [21.63] vs 37.67 [11.01] ng · h/mL [P = 0.007] and 27.08 [2.72] ng · h/mL [P = 0.016]).,Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30017169/),[h·ng] / [ml],27.08,190507,DB00208,Ticlopidine
,25577873,K12,"The population typical values of K12, CL/F, V/F, EC50, K(in), and E(max) were 0.259 h(-1), 179 L x h(-1), 632 L, 1.57 ng x mL(-1), 4.29 and 0.664, respectively.",[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25577873/),1/[h],0.259,192051,DB00208,Ticlopidine
,25577873,E(max),"The population typical values of K12, CL/F, V/F, EC50, K(in), and E(max) were 0.259 h(-1), 179 L x h(-1), 632 L, 1.57 ng x mL(-1), 4.29 and 0.664, respectively.",[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25577873/),,0.664,192052,DB00208,Ticlopidine
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,31,195243,DB00208,Ticlopidine
,34114623,trough levels,There were no significant differences in the primary endpoint (trough levels of VASP-PRI following ticagrelor 90 mg dosing) between cohorts (31 ± 20 vs 25 ± 14; p = 0.105).,Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34114623/),,25,195244,DB00208,Ticlopidine
,9408023,percent in,"The percent inhibition of platelet aggregation induced by ADP 5 microM at the end of tirofiban infusion in periods 1 and 2 was 73.6 +/- 2.6 and 87.1 +/- 5.7% (mean +/- SD), respectively.",Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408023/),%,73.6,197064,DB00208,Ticlopidine
,9408023,percent in,"The percent inhibition of platelet aggregation induced by ADP 5 microM at the end of tirofiban infusion in periods 1 and 2 was 73.6 +/- 2.6 and 87.1 +/- 5.7% (mean +/- SD), respectively.",Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408023/),%,87.1,197065,DB00208,Ticlopidine
,7274310,terminal half-life,The plasma concentration/time curve displayed a biphasic profile and the terminal half-life of Ticlopidine was tentatively estimated to be 6-10 h in the rat.,"Metabolism of ticlopidine in rats: identification and quantitative determination of some its metabolites in plasma, urine and bile. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7274310/),h,6-10,199048,DB00208,Ticlopidine
,26080512,Cmax,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [l],1.97,200543,DB00208,Ticlopidine
,26080512,Cmax,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [l],2.48,200544,DB00208,Ticlopidine
,26080512,AUC0-∞,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [h·l],8.44,200545,DB00208,Ticlopidine
,26080512,AUC0-∞,"The value of Cmax and AUC0-∞ of ginsenoside Rg, were increased from 1.97 ± 0.44 mg/L and 8.44 ± 2.64 mg/L · h to 2.48 ± 0.63 mg/L and 14.38 ± 5.72 mg/L · h respectively.",[Effect of Clopidogrel on Pharmacokinetic of Fufang Danshen Dripping Pill (FDDP)]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26080512/),[mg] / [h·l],14.38,200546,DB00208,Ticlopidine
,7848332,ED50,"In dog coronary stenosis, LCB 2853 shown a very high efficacy (ED50 = 7.2 micrograms/kg), whereas acetylsalicylic acid (ASA) was only active at 3.2 mg/kg and ticlopidine was ineffective at 12.8 mg/kg.",Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848332/),[μg] / [kg],7.2,204977,DB00208,Ticlopidine
,7848332,ED50,"In rat venous thrombosis induced by combination of venous injury and blood stasis, perfused LCB 2853 decreased the weight of thrombi in a dose related manner (ED50 = 220 micrograms/kg/min).",Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848332/),[μg] / [kg·min],220,204978,DB00208,Ticlopidine
,20206794,ma,"In Chinese subjects, mean maximal IPA (87%) occurred 1 hour after prasugrel dosing; in white subjects, mean maximal IPA (78%) occurred 2 hours after prasugrel dosing.",Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206794/),%,87,205173,DB00208,Ticlopidine
,20206794,maximal IPA,"After administration of Clopidogrel 300 mg in Chinese subjects, mean maximal IPA (58%) occurred at 4 hours.",Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206794/),%,58,205174,DB00208,Ticlopidine
,23016453,peak plasma concentration (Cmax),"The peak plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration versus time curve from time 0 h to 36 h (AUC(0-36)), elimination half-life (t1/2), clearance rate (CL/F) and apparent volume of distribution (Vd) were (1.804 +/- 1.706) ng/ml, (0.7 +/- 0.3) h, (2.465 +/- 1.693) ng x h/ml, (7.3 +/- 7.0) h, (53.09 +/- 34.65) x 10(3) L/h and (447.1 +/- 440.8) x 10(3) L, respectively.",Pharmacokinetics of clopidogrel in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016453/),[ng] / [ml],1.804,206250,DB00208,Ticlopidine
,23016453,apparent volume of distribution (Vd),"The peak plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration versus time curve from time 0 h to 36 h (AUC(0-36)), elimination half-life (t1/2), clearance rate (CL/F) and apparent volume of distribution (Vd) were (1.804 +/- 1.706) ng/ml, (0.7 +/- 0.3) h, (2.465 +/- 1.693) ng x h/ml, (7.3 +/- 7.0) h, (53.09 +/- 34.65) x 10(3) L/h and (447.1 +/- 440.8) x 10(3) L, respectively.",Pharmacokinetics of clopidogrel in healthy Chinese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23016453/),l,447.1,206251,DB00208,Ticlopidine
,30326264,tmax,"In the single-ascending-dose study, vicagrel was metabolized rapidly with the median tmax for the three metabolites, namely, H4, H3, and SM3, ranging from 0.25-1.75 h.","Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.25-1.75,207785,DB00208,Ticlopidine
,30326264,tmax,The median tmax for active H4 in the vicagrel 5 mg group was slightly shorter than that in the clopidogrel 75 mg group (0.50 versus 0.75 h).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.50,207786,DB00208,Ticlopidine
,30326264,tmax,The median tmax for active H4 in the vicagrel 5 mg group was slightly shorter than that in the clopidogrel 75 mg group (0.50 versus 0.75 h).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.75,207787,DB00208,Ticlopidine
,30326264,AUC0-t,The mean AUC0-t for H4 in the vicagrel 5 mg group was similar to that in the clopidogrel 75 mg group (11.7 versus 11.8 ng∙h/mL).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),[ng∙h] / [ml],11.7,207788,DB00208,Ticlopidine
,30326264,AUC0-t,The mean AUC0-t for H4 in the vicagrel 5 mg group was similar to that in the clopidogrel 75 mg group (11.7 versus 11.8 ng∙h/mL).,"Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),[ng∙h] / [ml],11.8,207789,DB00208,Ticlopidine
,30326264,tmax,"In the loading-dose study, for active H4, the median tmax was slightly shorter (0.50 versus 0.75 h) and the mean AUC0-t was 29% higher in the vicagrel 20 mg group than those in the clopidogrel 300 mg group.","Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.50,207790,DB00208,Ticlopidine
,30326264,tmax,"In the loading-dose study, for active H4, the median tmax was slightly shorter (0.50 versus 0.75 h) and the mean AUC0-t was 29% higher in the vicagrel 20 mg group than those in the clopidogrel 300 mg group.","Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326264/),h,0.75,207791,DB00208,Ticlopidine
<,27511819,time to maximal plasma concentration,"Results from pharmacokinetic (PK) studies showed that ClopNPT released the active metabolite with a time to maximal plasma concentration of <5 minutes in C57BL/6 mice after either oral or intravenous administration, and plasma concentrations of the active metabolite reached Cmax values of 1242 and 1100 ng/ml after a 10-mg/kg oral dose and a 5-mg/kg intravenous dose, respectively.",Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511819/),min,5,209096,DB00208,Ticlopidine
,27511819,Cmax,"Results from pharmacokinetic (PK) studies showed that ClopNPT released the active metabolite with a time to maximal plasma concentration of <5 minutes in C57BL/6 mice after either oral or intravenous administration, and plasma concentrations of the active metabolite reached Cmax values of 1242 and 1100 ng/ml after a 10-mg/kg oral dose and a 5-mg/kg intravenous dose, respectively.",Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511819/),[ng] / [ml],1242,209097,DB00208,Ticlopidine
,27511819,Cmax,"Results from pharmacokinetic (PK) studies showed that ClopNPT released the active metabolite with a time to maximal plasma concentration of <5 minutes in C57BL/6 mice after either oral or intravenous administration, and plasma concentrations of the active metabolite reached Cmax values of 1242 and 1100 ng/ml after a 10-mg/kg oral dose and a 5-mg/kg intravenous dose, respectively.",Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511819/),[ng] / [ml],1100,209098,DB00208,Ticlopidine
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],12.8,212063,DB00208,Ticlopidine
,24043374,AUC(0-tlast),Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL.,"Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24043374/),[h·ng] / [ml],17.9,212064,DB00208,Ticlopidine
,26068527,AUC0-t,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],9850,212918,DB00208,Ticlopidine
,26068527,AUC0-t,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],"27,300",212919,DB00208,Ticlopidine
,26068527,AUC0-∞,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],9850,212920,DB00208,Ticlopidine
,26068527,AUC0-∞,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[μg] / [h·l],"27,600",212921,DB00208,Ticlopidine
,26068527,t1/2,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),h,2.07,212922,DB00208,Ticlopidine
,26068527,t1/2,"3. After pretreatment with high dose of fluvoxamine (27 mg/kg), there were significant increases in the AUC0-t (from 9850±4060 to 27,300±6910 µg/l h; p<0.05), AUC0-∞ (from 9850±4060 to 27,600±6800 µg/l h; p<0.05) and t1/2 (from 2.07±0.0942 to 7.49±1.22 h; p<0.05) of clopidogrel carboxylic acid.",Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),h,7.49,212923,DB00208,Ticlopidine
,26068527,VLz/F,The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0.765±0.299 to 0.256±0.0594 l/kg; p<0.05) after pretreatment with high dose of fluvoxamine.,Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[l] / [kg],0.765,212924,DB00208,Ticlopidine
,26068527,VLz/F,The pharmacokinetic data for clopidogrel carboxylic acid showed significant decreases in VLz/F (from 0.765±0.299 to 0.256±0.0594 l/kg; p<0.05) after pretreatment with high dose of fluvoxamine.,Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26068527/),[l] / [kg],0.256,212925,DB00208,Ticlopidine
,29154109,flow rate,"The mobile phase was acetonitrile-water-formic acid (45:55:0.0275, v/v/v) delivered at a flow rate of 0.45mL/min under isocratic elution.",Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29154109/),[ml] / [min],0.45,213288,DB00208,Ticlopidine
,29154109,total chromatographic run time,The total chromatographic run time was 6min.,Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29154109/),min,6,213289,DB00208,Ticlopidine
,31034271,Time to maximum concentration,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.54,213428,DB00208,Ticlopidine
,31034271,Time to maximum concentration,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.71,213429,DB00208,Ticlopidine
,31034271,terminal-phase half-life,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,1.81,213430,DB00208,Ticlopidine
,31034271,terminal-phase half-life,"Time to maximum concentration of clopidogrel and CAMD was 0.54 and 0.71 hours, respectively, and calculated terminal-phase half-life of clopidogrel and CAMD was 1.81 and 0.97 hours, respectively.",Pharmacokinetics and competitive pharmacodynamics of ADP-induced platelet activation after oral administration of clopidogrel to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31034271/),h,0.97,213431,DB00208,Ticlopidine
,19698014,time to peak plasma concentration,"Absorption is complete and rapid, with mean time to peak plasma concentration of approximately 30 minutes for R-138727.","Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698014/),min,30,217918,DB00208,Ticlopidine
,19698014,plasma half-life,"Median plasma half-life of the active metabolite is approximately 4 hours, and excretion is mainly urinary.","Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19698014/),h,4,217919,DB00208,Ticlopidine
,22169056,run time,"The method was validated across the clinically relevant concentration range of 0.01-50 ng/mL for parent clopidogrel and 0.1-150 ng/mL (r(2)=0.99) for CAMD, with a fast run time of 1.5 min to support pharmacokinetic studies using 75, 150, or 300 mg oral doses of clopidogrel.",A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169056/),min,1.5,219562,DB00208,Ticlopidine
,26825365,time to maximal plasma clopidogrel concentration (t max),"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,0.83,220348,DB00208,Ticlopidine
,26825365,time to maximal plasma clopidogrel concentration (t max),"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,0.91,220349,DB00208,Ticlopidine
,26825365,terminal elimination half-life,"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,3.99,220350,DB00208,Ticlopidine
,26825365,terminal elimination half-life,"The respective Clopacin(®) and reference drug values for mean time to maximal plasma clopidogrel concentration (t max) were 0.83 and 0.91 h, and for terminal elimination half-life were 3.99 and 3.51 h.","Pivotal Bioequivalence Study of Clopacin®, a Generic Formulation of Clopidogrel 75 mg Film-Coated Tablets. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26825365/),h,3.51,220351,DB00208,Ticlopidine
,20594086,maximum concentration,"Clopidogrel was not detected in any samples; in dogs given 1.13 +/- 0.17 mg/kg, maximum concentration of SR 26334 (mean +/- SD, 0.206 +/- 0.2 microg/mL) was detected 1 hour after administration.",Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20594086/),[μg] / [ml],0.206,221241,DB00208,Ticlopidine
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,171.4,221656,DB00208,Ticlopidine
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pru,146.3,221657,DB00208,Ticlopidine
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,173.7,221658,DB00208,Ticlopidine
,31136946,PRU,"No significant differences in PRU values were observed between the atorvastatin and rosuvastatin groups at the beginning of the study (171.4 ± 54.3 vs 146.3 ± 48.1 PRU, p = 0.192) as well as at six months (173.7 ± 45.8 vs 157.3 ± 54.9 PRU, p = 0.562).",Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31136946/),pr,157.3,221659,DB00208,Ticlopidine
,10613611,serum Cmin,All patients had serum Cmin ticlopidine values of 0.06 to 0.25 microg/mL when receiving ticlopidine.,Ticlopidine inhibits phenytoin clearance. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613611/),[μg] / [ml],0.06 to 0.25,224020,DB00208,Ticlopidine
,10613611,Km,Mean phenytoin Km significantly increased from 5.8 to 12.3 during ticlopidine coadministration compared with administration of phenytoin alone (P = .02).,Ticlopidine inhibits phenytoin clearance. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613611/),,5.8,224021,DB00208,Ticlopidine
,10613611,Km,Mean phenytoin Km significantly increased from 5.8 to 12.3 during ticlopidine coadministration compared with administration of phenytoin alone (P = .02).,Ticlopidine inhibits phenytoin clearance. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613611/),,12.3,224022,DB00208,Ticlopidine
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,322.2,225780,DB00208,Ticlopidine
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,211.9,225781,DB00208,Ticlopidine
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,264.1,225782,DB00208,Ticlopidine
,17472221,m/z transition,The multiple reaction monitoring was based on m/z transition of 322.2 --> 211.9 for clopidogrel and 264.1 --> 125.1 for ticlopidine (internal standard).,Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),,125.1,225783,DB00208,Ticlopidine
,17472221,total analytical run time,"The total analytical run time was relatively short (3 min), and the LLOQ was 10 pg/mL using 0.5 mL of human plasma.",Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472221/),min,3,225784,DB00208,Ticlopidine
,19402342,limit of detection (LOD),The limit of detection (LOD) of ticlopidine hydrochloride was 0.5 ng/mL.,Quantitative determination of ticlopidine hydrochloride in human plasma by high-performance liquid chromatography-electronspray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402342/),[ng] / [ml],0.5,225979,DB00208,Ticlopidine
more,19402342,extraction recovery,The extraction recovery of ticlopidine hydrochloride was more than 80%.,Quantitative determination of ticlopidine hydrochloride in human plasma by high-performance liquid chromatography-electronspray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19402342/),%,80,225980,DB00208,Ticlopidine
,25557828,AM,"Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL(-1) ; 95% CI, 10.96-14.72 ng mL(-1) ; and geometric mean, 12.55 ng mL(-1) ; 95% CI, 10.80-14.58 ng mL(-1) ; P = 0.91).",Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557828/),[ng] / [ml],12.70,229330,DB00208,Ticlopidine
,25557828,AM,"Clopidogrel AM levels were similar in patients randomized to aspirin 325 or 81 mg (geometric mean, 12.70 ng mL(-1) ; 95% CI, 10.96-14.72 ng mL(-1) ; and geometric mean, 12.55 ng mL(-1) ; 95% CI, 10.80-14.58 ng mL(-1) ; P = 0.91).",Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25557828/),[ng] / [ml],12.55,229331,DB00208,Ticlopidine
,26446447,unbound paclitaxel clearance,"Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726).",Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446447/),[l] / [h],238,240673,DB00208,Ticlopidine
,26446447,unbound paclitaxel clearance,"Estimated unbound paclitaxel clearance was 238 l h−1, which was only 62% of the cohort geometric mean (385 l h−1; range 176–726).",Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446447/),[l] / [h],385,240674,DB00208,Ticlopidine
,19634510,AUCinf,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],15773,241654,DB00208,Ticlopidine
,19634510,AUCinf,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],15691,241655,DB00208,Ticlopidine
,19634510,AUCt,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],"15,462",241656,DB00208,Ticlopidine
,19634510,AUCt,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[h·ng] / [ml],"15,315",241657,DB00208,Ticlopidine
,19634510,Cmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[ng] / [ml],4919,241658,DB00208,Ticlopidine
,19634510,Cmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),[ng] / [ml],4699,241659,DB00208,Ticlopidine
,19634510,tmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.84,241660,DB00208,Ticlopidine
,19634510,tmax,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.93,241661,DB00208,Ticlopidine
,19634510,t1/2,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,7.92,241662,DB00208,Ticlopidine
,19634510,t1/2,"In case of CCA the values of pharmacokinetic parameters were similar for the two products (test vs reference): AUCinf: 15773 vs. 15691 ng x h/mL, AUCt: 15,462 vs. 15,315 ng x h/mL, Cmax: 4919 vs. 4699 ng/mL, tmax: 0.84 vs. 0.93 h, t1/2: 7.92 vs. 8.41 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,8.41,241663,DB00208,Ticlopidine
,19634510,AUCinf,Pharmacokinetic parameters values of CBS were: AUCinf: 1.96 vs.,Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,1.96,241664,DB00208,Ticlopidine
,19634510,AUCt,"1.84 ng x h/mL (test vs reference), AUCt: 1.91 vs.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,1.91,241665,DB00208,Ticlopidine
,19634510,Cmax,"1.81 ng x h/mL, Cmax, 1.44 vs.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,1.44,241666,DB00208,Ticlopidine
,19634510,tmax,"1.52 ng/mL, tmax: 0.90 vs.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),,0.90,241667,DB00208,Ticlopidine
,19634510,t1/2,"0.99 h, t1/2: 0.74 vs. 0.57 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.74,241668,DB00208,Ticlopidine
,19634510,t1/2,"0.99 h, t1/2: 0.74 vs. 0.57 h.",Usefulness of the parent compound determination in bioequivalence evaluation of clopidogrel generic products. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19634510/),h,0.57,241669,DB00208,Ticlopidine
,10440420,Cmax,A Cmax of 3.9 mg-Eqv/L was reached after a median time of 1 hour (Tmax).,Pharmacokinetic profile of 14C-labeled clopidogrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),[mg-eqv] / [l],3.9,241798,DB00208,Ticlopidine
,10440420,time,A Cmax of 3.9 mg-Eqv/L was reached after a median time of 1 hour (Tmax).,Pharmacokinetic profile of 14C-labeled clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,1,241799,DB00208,Ticlopidine
,10440420,Tmax,A Cmax of 3.9 mg-Eqv/L was reached after a median time of 1 hour (Tmax).,Pharmacokinetic profile of 14C-labeled clopidogrel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,1,241800,DB00208,Ticlopidine
,10440420,"plasma elimination half-life, t1/2","The plasma elimination half-life, t1/2, ranged from 336 hours to 672 hours in Period I and from 275 to 433 hours in Period II.",Pharmacokinetic profile of 14C-labeled clopidogrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,336,241801,DB00208,Ticlopidine
,10440420,"plasma elimination half-life, t1/2","The plasma elimination half-life, t1/2, ranged from 336 hours to 672 hours in Period I and from 275 to 433 hours in Period II.",Pharmacokinetic profile of 14C-labeled clopidogrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,672,241802,DB00208,Ticlopidine
,10440420,"plasma elimination half-life, t1/2","The plasma elimination half-life, t1/2, ranged from 336 hours to 672 hours in Period I and from 275 to 433 hours in Period II.",Pharmacokinetic profile of 14C-labeled clopidogrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,275 to 433,241803,DB00208,Ticlopidine
,10440420,time to last measurable radioactivity,The radiocarbon excretion over 10 to 12 hours post-dose (time to last measurable radioactivity) in expired air represented 0.31 to 0.35% of the administered dose.,Pharmacokinetic profile of 14C-labeled clopidogrel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),h,10 to 12,241804,DB00208,Ticlopidine
,10440420,total excretion,Mean total excretion of radioactivity was 92% of the dose during Period I and 93% during Period II.,Pharmacokinetic profile of 14C-labeled clopidogrel. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),%,92,241805,DB00208,Ticlopidine
,10440420,total excretion,Mean total excretion of radioactivity was 92% of the dose during Period I and 93% during Period II.,Pharmacokinetic profile of 14C-labeled clopidogrel. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440420/),%,93,241806,DB00208,Ticlopidine
,23192851,transformation efficiency,"The transformation efficiency of vicagrel to 2-oxo-clopidogrel was 94%, but only 13% of clopidogrel was converted to 2-oxo-clopidogrel.","Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23192851/),%,94,245986,DB00208,Ticlopidine
,22706585,maximal,The maximal ADP-induced platelet aggregation (2 μmol/L) was decreased in EMs compared with PMs.,Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706585/),[μM] / [l],2,246160,DB00208,Ticlopidine
,27260150,half-life,"Clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) of pioglitazone 2.1-fold [P < 0.001, 90% confidence interval (CI) 1.8-2.6] and prolonged its half-life from 6.7 to 11 hours (P = 0.002).",Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260150/),h,6.7,249674,DB00208,Ticlopidine
,27260150,half-life,"Clopidogrel increased the area under the plasma concentration-time curve (AUC0-∞) of pioglitazone 2.1-fold [P < 0.001, 90% confidence interval (CI) 1.8-2.6] and prolonged its half-life from 6.7 to 11 hours (P = 0.002).",Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27260150/),h,11,249675,DB00208,Ticlopidine
,22515556,maximum (peak) plasma concentration (C(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],733,250416,DB00208,Ticlopidine
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.0,250417,DB00208,Ticlopidine
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],210,250418,DB00208,Ticlopidine
,22515556,time to C(max) (t(max)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),h,2.1,250419,DB00208,Ticlopidine
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],4130,250420,DB00208,Ticlopidine
,22515556,area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)),"In ONSET-OFFSET, maximum (peak) plasma concentration (C(max)), time to C(max) (t(max)) and area under the plasma concentration-time curve from time 0 to 8 hours (AUC(8)) for ticagrelor were 733 ng/mL, 2.0 hours and 4130 ng · h/mL, respectively; and for AR-C124910XX were 210 ng/mL, 2.1 hours and 1325 ng · h/mL, respectively.",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],1325,250421,DB00208,Ticlopidine
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],305,250422,DB00208,Ticlopidine
,22515556,Trough plasma ticagrelor,Trough plasma ticagrelor (305 ng/mL) and AR-C124910XX (121 ng/mL) concentrations were 5.2 and 7.7 times higher than respective concentration producing 50% of maximum effect (EC(50)) estimates.,Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],121,250423,DB00208,Ticlopidine
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],724,250424,DB00208,Ticlopidine
,22515556,C(max),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[ng] / [ml],764,250425,DB00208,Ticlopidine
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3983,250426,DB00208,Ticlopidine
,22515556,AUC(8),"In RESPOND, ticagrelor mean C(max) and AUC(8) following 2-week dosing were comparable between clopidogrel responders (724 ng/mL and 3983 ng · h/mL, respectively) and non-responders (764 ng/mL and 3986 ng · h/mL, respectively).",Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22515556/),[h·ng] / [ml],3986,250427,DB00208,Ticlopidine
,18030066,area under the concentration-time curve (AUC0-tlast),Active metabolite area under the concentration-time curve (AUC0-tlast) after prasugrel 60-mg (594 ng.hr/mL) was 2.2 times that after clopidogrel 600-mg.,Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030066/),[h·ng] / [ml],594,252650,DB00208,Ticlopidine
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,70.42,254540,DB00208,Ticlopidine
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,69.45,254541,DB00208,Ticlopidine
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,65.58,254542,DB00208,Ticlopidine
,26386578,maximum effect,"The maximum effect of P2Y12 receptor inhibition assessed by flow cytometry using VASP was 70.42 (6.7), 69.45 (7.1), and 65.58 (12.6) for intravenous MDCO-157 at doses of 75, 150, and 300 mg, respectively, compared with 56.6 (17.5) with oral clopidogrel 300 mg administration (p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),,56.6,254543,DB00208,Ticlopidine
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],3.6,254544,DB00208,Ticlopidine
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],6.9,254545,DB00208,Ticlopidine
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],12.4,254546,DB00208,Ticlopidine
,26386578,Plasma exposure,"Plasma exposure of H4-thiol also increased with intravenous dose (3.6 ± 2.6, 6.9 ± 4.6, and 12.4 ± 9.1 h·ng/ml for intravenous 75, 150, and 300 mg, respectively) but was lower than with oral administration of a 300-mg dose (34.0 ± 16.0 h.ng/ml; pairwise p < 0.0001).",Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26386578/),[h·ng] / [ml],34.0,254547,DB00208,Ticlopidine
,9210444,absolute recovery,"The compounds were isolated from plasma by Bond Elut C18 solid-phase extraction, the mean absolute recovery was 84.9%.",Liquid chromatographic method for the determination of ticlopidine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210444/),%,84.9,261478,DB00208,Ticlopidine
,9210444,limit of quant,"The limit of quantitation was 10 ng ml(-1), the limit of detection was 5 ng ml(-1).",Liquid chromatographic method for the determination of ticlopidine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210444/),[ng] / [ml],10,261479,DB00208,Ticlopidine
,9210444,limit of detection,"The limit of quantitation was 10 ng ml(-1), the limit of detection was 5 ng ml(-1).",Liquid chromatographic method for the determination of ticlopidine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210444/),[ng] / [ml],5,261480,DB00208,Ticlopidine
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,706,265349,DB00208,Ticlopidine
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,221,265350,DB00208,Ticlopidine
,17076696,bleeding time,"On day 10 at 4 h postdose, bleeding time was prolonged with prasugrel 10 mg (prasugrel 10 mg, 706 +/- 252 s vs. placebo, 221 +/- 38 s, P = 0.05) but not with clopidogrel (283 +/- 56 s, P = 0.98).","A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17076696/),s,283,265351,DB00208,Ticlopidine
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,21,267874,DB00208,Ticlopidine
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,1.,267875,DB00208,Ticlopidine
,16637000,linear dynamic,The assay exhibited a linear dynamic range of 5-6000 pg/mL for clopidogrel in human plasma.,Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637000/),[pg] / [ml],5-6000,268599,DB00208,Ticlopidine
,16637000,run time,A run time of 2.5 min for each sample made it possible to analyze more than 400 human plasma samples per day.,Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16637000/),min,2.5,268600,DB00208,Ticlopidine
,16423907,impedance,Mean (SD) impedance of the healthy cohort was 12.2 (2.2) Omega.,Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,12.2,268825,DB00208,Ticlopidine
<,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268826,DB00208,Ticlopidine
>,16423907,impedance,"The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance < or =5 Omega and >5 Omega, respectively.",Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16423907/),omega,5,268827,DB00208,Ticlopidine
,25256597,IC50,The IC50 value was 2.1 µM.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),μM,2.1,268846,DB00208,Ticlopidine
,25256597,AUC0-∞,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],0.9,268847,DB00208,Ticlopidine
,25256597,AUC0-∞,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],1.7,268848,DB00208,Ticlopidine
,25256597,Cmax,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],0.4,268849,DB00208,Ticlopidine
,25256597,Cmax,"After pretreatment with scutellarin, there were significant increases in the AUC0-∞ (from 0.9 ± 0.4 to 1.7 ± 0.6 ng/ml h; p <0.05) and Cmax (from 0.4 ± 0.1 to 0.9 ± 0.1 ng/ml; p <0.05) of clopidogrel.",Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],0.9,268850,DB00208,Ticlopidine
,25256597,AUC0-∞,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],18.2,268851,DB00208,Ticlopidine
,25256597,AUC0-∞,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [h·ml],11.4,268852,DB00208,Ticlopidine
,25256597,Cmax,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],8.2,268853,DB00208,Ticlopidine
,25256597,Cmax,The pharmacokinetic data for clopidogrel active metabolite showed significant decreases in AUC0-∞ (18.2 ± 5.6 to 11.4 ± 3.7 ng/ml h; p <0.05) and Cmax (from 8.2 ± 1.2 to 4.3 ± 0.3 ng/ml; p <0.05) after pretreatment with scutellarin.,Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25256597/),[ng] / [ml],4.3,268854,DB00208,Ticlopidine
,24127209,maximum plasma concentration [C max],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[ng] / [ml],5.29,269288,DB00208,Ticlopidine
,24127209,maximum plasma concentration [C max],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[ng] / [ml],7.13,269289,DB00208,Ticlopidine
,24127209,area under the plasma concentration-time curve from time zero to time t [AUC t ],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[h·ng] / [ml],7.37,269290,DB00208,Ticlopidine
,24127209,area under the plasma concentration-time curve from time zero to time t [AUC t ],"The pharmacokinetic parameter values for the H3 and H4 isomers determined in the studied group of patients treated with clopidogrel 75 mg (maximum plasma concentration [C max] 5.29 ± 5.54 and 7.13 ± 6.32 ng/mL for H3 and H4, respectively; area under the plasma concentration-time curve from time zero to time t [AUC t ] 7.37 ± 6.71 and 11.30 ± 9.58 ng·h/mL for H3 and H4, respectively) were lower than those reported in healthy volunteers, according to the literature data.",Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),[h·ng] / [ml],11.30,269291,DB00208,Ticlopidine
,24127209,Platelet,Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min.,Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),au·min,37 and 747,269292,DB00208,Ticlopidine
,24127209,aggregation,Platelet aggregation measured with a Multiplate analyser ranged between 37 and 747 AU·min.,Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24127209/),au·min,37 and 747,269293,DB00208,Ticlopidine
